As previously described, ADAR1 prevents dsRNA from activating the MDA5-MAVS signaling pathway by editing dsRNA, which in turn inhibits the increased expression of IFN and ISG, and this inhibition also affects the therapeutic effect on cancer. Here, ADAR is linked to cancer.